Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Addex Therapeutics' Cash & Equivalents rose 6128252570.25% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 6128252570.25%. This contributed to the annual value of $3.8 million for FY2024, which is 1174.34% down from last year.
  • Latest data reveals that Addex Therapeutics reported Cash & Equivalents of $2.7 million as of Q3 2025, which was up 6128252570.25% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Addex Therapeutics' Cash & Equivalents peaked at $4274.4 billion during Q2 2024, and registered a low of $4.43 during Q1 2024.
  • Its 4-year average for Cash & Equivalents is $285.0 billion, with a median of $4.0 million in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 10000.0% in 2023, then surged by 5524295183980076.0% in 2024.
  • Over the past 4 years, Addex Therapeutics' Cash & Equivalents (Quarter) stood at $7.2 million in 2022, then crashed by 39.66% to $4.4 million in 2023, then fell by 12.46% to $3.8 million in 2024, then fell by 28.32% to $2.7 million in 2025.
  • Its Cash & Equivalents stands at $2.7 million for Q3 2025, versus $4.0 million for Q2 2025 and $3.1 million for Q1 2025.